Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Wedgewood Partners. This analysis is provided for institutional research purposes only and is not investment advice.
"Wedgewood navigated a hyper-concentrated Q2 market by exiting underperforming UnitedHealth, trimming high-flying tech, and buying quality non-tech compounders like Zoetis at multi-year valuation lows."
In their Q2 2025 client letter, Wedgewood Partners reports a +7.1% net return for the quarter, underperforming the tech-dominated S&P 500 (+10.9%) and Russell 1000 Growth (+17.8%). The managers detail critical portfolio modifications, including the full liquidation of long-term holding UnitedHealth (UNH) due to major execution failures and spiked Medicare Advantage costs, and the initiation of a major new position in global animal health leader Zoetis (ZTS) at a highly attractive valuation. They highlight the extreme, narrow nature of the current bull market, noting that 54% of the Russell 1000 Growth Index is concentrated in just six stocks, and present their strategy of shifting capital into the 76% of S&P 500 industry groups currently trading at bargain relative valuations.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High-conviction positioning: Wedgewood navigated a hyper-concentrated Q2 market by exiting underperforming UnitedHealth, trimming high-flying tech, and buying quality non-tech compounders like Zoetis at multi-...
Growth Outlook
Market outlook remains moderate conviction: Wedgewood navigated a hyper-concentrated Q2 market by exiting underperforming UnitedHealth, trimming high-flying tech, and buying quality non-tech compounders like Zoetis at multi-...
Risk Appetite
Risk appetite posture is above average conviction: Wedgewood navigated a hyper-concentrated Q2 market by exiting underperforming UnitedHealth, trimming high-flying tech, and buying quality non-tech compounders like Zoetis at multi-...
Capital Deployment
Manager actively deployed capital into high-conviction opportunities. Wedgewood navigated a hyper-concentrated Q2 market by exiting underperforming UnitedHealth, trimming high-flying tech, and buying quality non-tech compounders like Zoetis at multi-...
Forward Guidance
Forward guidance signal: Wedgewood navigated a hyper-concentrated Q2 market by exiting underperforming UnitedHealth, trimming high-flying tech, and buying quality non-tech compounders like Zoetis at multi-...
Language Signal
Tone analysis indicates above average conviction language: Wedgewood navigated a hyper-concentrated Q2 market by exiting underperforming UnitedHealth, trimming high-flying tech, and buying quality non-tech compounders like Zoetis at multi-...
Perceived Risk
Perceived risk level is evaluated as above average conviction. Wedgewood navigated a hyper-concentrated Q2 market by exiting underperforming UnitedHealth, trimming high-flying tech, and buying quality non-tech compounders like Zoetis at multi-...
Opportunity Density
Opportunity density index indicates above average conviction actionable entry points. Wedgewood navigated a hyper-concentrated Q2 market by exiting underperforming UnitedHealth, trimming high-flying tech, and buying quality non-tech compounders like Zoetis at multi-...
Time Horizon
Investment time horizon reflects a high conviction orientation. Wedgewood navigated a hyper-concentrated Q2 market by exiting underperforming UnitedHealth, trimming high-flying tech, and buying quality non-tech compounders like Zoetis at multi-...
